Clinical Trials Browser

Phase 1/2 × tozuleristide × 90 days × Clear all

NCT05316688 2026-02-25

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms